Navigation Links
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
Date:6/24/2010

Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Madison, WI (Vocus) June 24, 2010 -- Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Prevagen showed statistically significant improvement over placebo at Day 60 in measures of spatial working memory and executive function in thirty five generally healthy adults reporting memory concerns prior to the start of the trial. The Prevagen arm showed a 14% reduction in the number of total errors compared to Day 0. The average age of this initial cohort was 61 years old and sixty eight percent of the participants were female. A statistically significant improvement was also seen in the change from baseline (Day 0) measurements. “We are encouraged by what this preliminary look at the data from this study has shown us,” said KC Lerner, Manager of Business Development.

Prevagen contains the calcium-binding protein apoaequorin. Apoaequorin has demonstrated neuroprotection in pre-clinical studies performed at the University of Wisconsin-Milwaukee. Apoaequorin was originally isolated from Aequorea victoria, a species of jellyfish found in the Puget Sound.

“The relationship between intracellular calcium imbalance and age-related cognitive decline is well-established. The data shows that Prevagen is a new tool for staying cognitively fit as we age. With 78 million baby boomers getting older every day, helping people with memory concerns is our first priority,” said Quincy Bioscience President Mark Underwood. Quincy Bioscience is also looking at several health conditions that are believed to be the result of disruptions in calcium homeostasis and intends to study the effect of Prevagen in these conditions.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/quincybioscience/memorydata/prweb4188374.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
2. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
3. Euthymics Bioscience Collaborates with GlobalSign and SafeNet to Provide an FDA Approved Electronic Signature Solution
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
5. Thriving Bioscience Region Leaves Its Mark
6. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
7. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
10. Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
11. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: